TD Asset Management Inc Boosts Stake in Kyverna Therapeutics, Inc. $KYTX

Key Points

• TD Asset Management Inc increased its stake in Kyverna Therapeutics by 179.5%, owning 252,196 shares worth approximately $774,000 at the end of the latest quarter.
• Several analysts have mixed views on Kyverna, with Wells Fargo raising its price target from $24 to $27 and setting an "overweight" rating, while Weiss Ratings maintained a "sell" rating.
• Kyverna Therapeutics is focused on developing cell therapies for autoimmune diseases, with its lead product candidate KYV-101 in active clinical trials.

TD Asset Management Inc increased its position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 179.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 252,196 shares of the company's stock after buying an additional 161,954 shares during the period. TD Asset Management Inc owned about 0.58% of Kyverna Therapeutics worth $774,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC boosted its holdings in Kyverna Therapeutics by 25.2% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 19,122 shares of the company's stock worth $59,000 after buying an additional 3,847 shares during the period. Rhumbline Advisers boosted its holdings in shares of Kyverna Therapeutics by 22.0% during the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company's stock valued at $61,000 after purchasing an additional 5,694 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Kyverna Therapeutics by 41.6% during the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company's stock valued at $81,000 after purchasing an additional 6,400 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Kyverna Therapeutics during the 1st quarter valued at about $92,000. Finally, Bank of New York Mellon Corp raised its position in shares of Kyverna Therapeutics by 22.2% during the 1st quarter. Bank of New York Mellon Corp now owns 48,784 shares of the company's stock valued at $94,000 after buying an additional 8,851 shares in the last quarter. Institutional investors own 18.08% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Weiss Ratings reissued a "sell (e+)" rating on shares of Kyverna Therapeutics in a research note on Tuesday, October 14th. William Blair began coverage on shares of Kyverna Therapeutics in a report on Wednesday, August 20th. They set an "outperform" rating on the stock. Wells Fargo & Company lifted their price objective on shares of Kyverna Therapeutics from $24.00 to $27.00 and gave the company an "overweight" rating in a report on Wednesday, October 8th. Finally, HC Wainwright lifted their price target on shares of Kyverna Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, August 29th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $19.00.

Kyverna Therapeutics Stock Performance

Shares of Kyverna Therapeutics stock opened at $6.67 on Thursday. The company has a market cap of $288.48 million, a P/E ratio of -1.81 and a beta of 3.72. The firm has a 50-day simple moving average of $5.09 and a two-hundred day simple moving average of $3.62. Kyverna Therapeutics, Inc. has a fifty-two week low of $1.78 and a fifty-two week high of $7.73.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.97) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.03. Equities research analysts forecast that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.

Want to see what other hedge funds are holding KYTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.